Investor Relations

Defining a new hundred-billion-level treatment category and market track.

Project Investment Highlights

Track Scarcity

The world's first new paradigm of "Immune Surgery and Universal Treatment for various solid tumors", leading a forward-looking blank track with an ocean market worth hundreds of billions.

Clinical Advantage

Over 100,000 treatments with mature efficacy. Total disease control rate (CR+PR+SD) of over 92.63%. Extremely low severe adverse reaction rate of only 0.19%.

Efficient Filing Path

IOS-1 granted orphan drug designation by FDA. Successfully completed FDA Pre-IND meeting in 2018, expected to bypass Phase I and directly enter Phase III.

Huge Growth Potential

A single indication (like pancreatic cancer) can support a market space of billions. Expanding to 19 other rare tumors and high-incidence solid tumors.

Mark Harris Testimonial

Clinical Validation: A Patient's Journey

Real-world evidence of our platform's life-saving potential.

"I was diagnosed with Stage 4 Prostate Cancer in June 2016... After 4 treatments of SONATA cancer therapy... my UCLA Health System Oncologist advised that all cancerous lesions that had been in my bones had disappeared."

- Mark E. Harris (US Patient)

The Power of Trust & Efficacy
  • 2016 - Defying the Odds: Top US medical systems offered little hope for his Stage 4 Prostate Cancer with systemic bone metastasis. Our Immune Slow Release Therapy eliminated the bone metastases within months.
  • 2023 - Returning for Hope: When his wife was diagnosed with lung cancer and conventional chemotherapy failed, Mark did not hesitate to cross the ocean again to seek Dr. Yu's treatment.
  • Investment Implication: Deep patient trust built on undeniable clinical outcomes, demonstrating significant advantages over traditional therapies in late-stage, complex oncology cases.
Business Model

"1+1+1" Three-Track Revenue Model

A value upgrade from "treatment plan" to "treatment platform" with diversified and highly resilient revenue structure.

1
Track 1: Direct Sales (To H/B)

Sales of core products (IOS-1) and specialized devices to large and medium-sized hospitals globally.

2
Track 2: Platform Empowerment (To B)

Solution licensing and technical services for a wide medical network (SaaS + consumables model).

3
Track 3: Ecosystem Co-construction

A global partnership program for national/regional markets forming joint ventures.

Financing & IPO Roadmap

Series A Funding Requirement: $50 Million

To systematically advance the core pipeline IOS-1 new drug from pharmaceutical development to listing applications in China and the United States (IND approval to NDA/BLA submission).

Targeting NASDAQ Capital Market

Projecting IPO between 2028 and 2029 to build international credibility and realize liquidity premium.